Recursion Pharmaceuticals, Inc. Overview
Pro stress-test →Recursion Pharmaceuticals is a clinical-stage TechBio company that uses AI-driven technology to decode biology and accelerate drug discovery. The company develops a proprietary platform called the Recursion OS—an AI-native, end-to-end drug discovery and development system integrating biology, chemistry, and clinical development.
Strategic Profile
Pro stress-test →Recursion differentiates itself through its integration of wet labs, bioinformatics, and NVIDIA-backed supercomputing (BioHive-2) to generate millions of multi-omic data points weekly and train machine learning models at scale. The company has established strategic partnerships with major pharma (Roche, Genentech, Takeda, Bayer) and is advancing a pipeline across oncology, rare disease, and neuroscience with multiple programs in clinical trials.
Competitive Landscape
Pro stress-test →Recursion competes in the emerging AI-native drug discovery space against companies like Exscientia, Tempus AI, and Atomwise, while also competing with traditional biotech on pipeline basis. Its differentiation lies in integrated wet-dry lab infrastructure and proprietary supercomputing, but success requires clinical validation of its AI-designed programs, which remain largely early-stage.
Industry Context
Recursion Pharmaceuticals, Inc. operates in Biotechnology / AI-Driven Drug Discovery (TechBio).
Key facts
Founded: 2013 · Headquarters: Salt Lake City, United States · Revenue: $58M · Market cap: $1.92B